Vessel Due F capsules 250 LE 50 pcs
Condition: New product
961 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Sulodexide
Release form
Capsules
Composition
1 caps: sulodexide 250 LE * Auxiliary substances: sodium lauryl sarcosinate - 3.3 mg, colloidal silicon dioxide - 3 mg, triglycerides - 86.1 mg.
Pharmacological effect
Anticoagulant direct action. The active substance of the drug Wessel Due f - sulodexide - is a natural product, extracted and isolated from the mucous membrane of the small intestine of the pig. It is a natural mixture of glycosaminoglycans: a heparin-like fraction with a molecular weight of 8,000 daltons (80%) and dermatan sulfate (20%). It has an anticoagulant, antithrombotic, angioprotective and profibrinolytic effect. antithrombotic action is associated with the suppression of activated X factor, increased synthesis and secretion of prostacyclin (PG I2), with a decrease in plasma fibrinogen levels. Roofibrinolytic effect is due to an increase in the level of tissue plasminogen activator in the blood and a decrease in its inhibitor content. The angioprotective action mechanism is associated with the restoration of the structural and functional integrity of vascular endothelium cells, the restoration of the normal density of the negative electrical charge of the basal vascular membrane. by reducing triglycerides (because it stimulates the lipolytic enzyme - lipoprot Elylipase, hydrolyzing triglycerides, which are part of LDL). The effectiveness of the drug in diabetic nephropathy is determined by the ability of sulodexide to reduce the thickness of the basement membrane and the production of extracellular matrix by reducing the proliferation of mesangium cells.
Pharmacokinetics
Absorption and distribution After oral administration, sulodexide is absorbed from the small intestine. 90% of sulodexide is absorbed by the vascular endothelium, which exceeds its concentration in the tissues of other organs by 20–30 times. Metabolism Metabolized in the liver and kidneys. Unlike unfractionated heparin and low molecular weight heparins, sulodexide does not desulfate,which leads to a decrease in antithrombotic activity and significantly speeds up the elimination from the body. Excretion Excreted by the kidneys 4 hours after administration.
Indications
- Angiopathies with an increased risk of thrombosis, incl. and after myocardial infarction; cerebral circulation, including an acute period of ischemic stroke, a period of early recovery; - dyscirculatory encephalopathy due to atherosclerosis, diabetes, arterial hypertension; - vascular dementia; - phlebopathy, deep vein thrombosis; - microangiopathy (nephropathy, retinopathy, neuropathy); - macroangiopathy with diabetes mellitus (diabetic syndrome th foot, encephalopathy, cardiomyopathy); - thrombophilic state, antiphospholipid syndrome (administered together with acetylsalicylic acid, and after LMWH) - treatment of thrombotic heparin-induced thrombocytopenia (as the drug does not cause and do not worsen it).
Contraindications
- hemorrhagic diathesis and diseases accompanied by low blood clotting; - I trimester of pregnancy; - hypersensitivity to the components of the drug.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
Use in the first trimester of pregnancy is contraindicated. There is a positive experience with sulodexide in patients with type 1 diabetes in the second and third trimesters of pregnancy for the treatment and prevention of vascular complications during the development of late toxicosis of pregnant women. Use the drug Wessel Due F in pregnancy in II and III trimesters should be strictly under the supervision of a physician. Data on the use of the drug during lactation (breastfeeding) is not provided.
Dosage and administration
At the beginning of therapy, the drug is injected parenterally in / m or / in (bolus or drip) 2 ml (1 ampoule) of solution for injection (600 LU) for 15-20 days. To prepare the solution for the on / in the introduction of the contents of 1 ampoule diluted in 150-200 ml of saline. Then move on to the drug inside.Assign 1 capsule (250 LU) 2 times / day for 30-40 days. Capsules are taken between meals. The full course of treatment should be repeated at least 2 times a year. Depending on the results of the patient’s clinical diagnostic examination, the dosing regimen may be changed.
Side effects
On the part of the digestive system: nausea, vomiting, epigastric pain. Allergic reactions: skin rash of different localization. Local reactions: pain, burning, hematoma at the injection site.
Overdose
Symptoms: bleeding or bleeding. Treatment: drug withdrawal; if necessary, conduct symptomatic therapy.
Interaction with other drugs
Clinically significant interaction of the drug Vessel Due f with other drugs has not been established. When using sulodexide it is not recommended to use anticoagulants (direct and indirect) and antiplatelet agents simultaneously.
special instructions
When using the drug, control of the coagulogram is necessary. At the beginning and end of treatment, it is advisable to determine the following indicators: APTT, antithrombin III, bleeding time and clotting time. Wessel Due F increases normal APTTs by approximately 1.5 times. Impact on ability to drive vehicles and control mechanisms The drug does not affect the ability to drive vehicles and control mechanisms.